Y. Shing

发表

Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth

William Arbuthnot Sir Lane, J. Folkman, B. Olsen, 1997, Cell.

Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor.

R. D'Amato, J. Folkman, A. Adamis, 1996, Australian and New Zealand journal of ophthalmology.

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

Lars Holmgren, Yihai Cao, J. Folkman, 1994, Cell.

Purification and characterization of heparin-binding endothelial cell growth factors.

M. Klagsbrun, P. D'Amore, Y. Shing, 1986, The Journal of biological chemistry.

Angiogenesis is stimulated by a tumor‐derived endothelial cell growth factor

J. Folkman, M. Klagsbrun, C. Haudenschild, 1985, Journal of cellular biochemistry.

Human betacellulin, a member of the EGF family dominantly expressed in pancreas and small intestine, is fully active in a monomeric form.

J. Folkman, M. Seno, H. Yamada, 1996, Growth factors.

Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction.

T. Watanabe, J. Folkman, K. Igarashi, 1994, The Journal of biological chemistry.

Angiogenesis Inhibition by Angiostatin, Endostatin and TNP-470 Prevents Cyclophosphamide Induced Cystitis

D. Jonas, W. Bentas, K. Camphausen, 2004, Angiogenesis.

Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth.

William Arbuthnot Sir Lane, J. Folkman, M. Moses, 1994, Cold Spring Harbor symposia on quantitative biology.

An Endogenous Inhibitor of Angiogenesis derived from a Transitional Cell Carcinoma: Clipped β2-Glycoprotein-I

D. Jonas, K. Camphausen, J. Folkman, 2006, Annals of Surgical Oncology.

The fate of intravenously administered bFGF and the effect of heparin.

J. Folkman, Y. Shing, J Folkman, 1989, Growth factors.

Biaffinity chromatography of fibroblast growth factors.

Y. Shing, 1991, Methods in enzymology.

Affinity of fibroblast growth factors for β-cyclodextrin tetradecasulfate

P. B. Weisz, J. Folkman, W. R. Ewing, 1990 .

[4] Purification of polypeptide growth factors from milk

M. Klagsbrun, Y. Shing, S. Davidson, 1987 .

Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing.

S. Szabó, J. Folkman, M. Stovroff, 1991, Annals of surgery.

Betacellulin: a mitogen from pancreatic beta cell tumors.

D. Hanahan, J. Folkman, G. Christofori, 1993, Science.

Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice.

J. Folkman, W. Beecken, E. Achilles, 2001, Journal of the National Cancer Institute.

Sucrose octasulfate regulates fibroblast growth factor‐2 binding, transport, and activity: Potential for regulation of tumor growth

M. Nugent, D. Panigrahy, A. Kaipainen, 2008, Journal of cellular physiology.

Control of angiogenesis by heparin and other sulfated polysaccharides.

J. Folkman, Y. Shing, J Folkman, 1992, Advances in experimental medicine and biology.

Multiple forms of angiostatin induce apoptosis in endothelial cells.

N. Bouck, S. Mandriota, G. Grau, 1998, Blood.

Suppression of tumor growth with recombinant murine angiostatin.

J. Folkman, Y. Shing, M. O'Reilly, 1997, Biochemical and biophysical research communications.

Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane.

J. Folkman, M. Nguyen, Y. Shing, 1994, Microvascular research.

Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice.

J. Folkman, W. Beecken, D. Panigrahy, 2000, Urology.

HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis.

M. Moses, Y. Shing, J. Fang, 2001, Cancer research.

Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model.

M A Moses, J. Harper, D. Wiederschain, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Multiple forms of basic fibroblast growth factor: amino-terminal cleavages by tumor cell- and brain cell-derived acid proteinases.

M. Klagsbrun, J. Smith, Y. Shing, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Clinical relevance of maspin expression in bladder cancer

D. Jonas, K. Camphausen, T. Engl, 2006, World Journal of Urology.

Purification of endothelial cell growth factors by heparin affinity chromatography.

M. Klagsbrun, R. Rybka, Y. Shing, 1987, Methods in enzymology.

during Early Tumorigenesis Factor , Is Important in the Switch to the Angiogenic Phenotype Growth Factor , Independent of Basic Fibroblast Growth-mediated Up-Regulation of Vascular Endothelial α HIF-1 Updated

M. Moses, Y. Shing, Li Yan, 2001 .

Advances in Brief HIF-1 a-mediated Up-Regulation of Vascular Endothelial Growth Factor , Independent of Basic Fibroblast Growth Factor , Is Important in the Switch to the Angiogenic Phenotype during Early Tumorigenesis 1

M. Moses, Y. Shing, Li Yan, 2001 .

Angiogenesis and Growth Factors in Ulcer Healing

S. Szabó, Y. Shing, Xiaoming Deng, 2002 .

Cloning and expression of cDNA encoding human betacellulin, a new member of the EGF family.

J. Folkman, Y. Ono, K. Igarashi, 1993, Biochemical and Biophysical Research Communications - BBRC.

Heparin-copper biaffinity chromatography of fibroblast growth factors.

Y. Shing, 1988, The Journal of biological chemistry.

Production of matrix metalloproteinases and a metalloproteinase inhibitor by swarm rat chondrosarcoma.

M. Moses, Y. Shing, 1994, Biochemical and biophysical research communications.